What is it prescribed for? OJEMDA, approved on April 23, 2024, is indicated for the treatment of patients 6 months of age and older with relapsed or refractory pediatric lowgrade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. What is the name of the drug and what does it do? Ojemda (pronounced oh-JEM-dah), (generic name: tovorafenib),...
What is it prescribed for? VOYDEYA, approved on April 1, 2024, is indicated as add-on therapy to ravulizumab or eculizumab for the treatment of extravascular hemolysis (EVH) in adults with paroxysmal nocturnal hemoglobinuria. What is the name of the drug and what does it do? Voydeya (pronounced voy-DAY-uh), (generic name: danicopan), is a medication indicated as an...
What is the name of the drug and what does it do? Itovebi (pronounced eye-TOH-veh-bee), generic name inavolisib, is a prescription medication used in combination with two other drugs, palbociclib and fulvestrant, to treat adults with certain types of advanced or metastatic breast cancer. This treatment is specifically for hormone receptor-positive, HER2-negative...
What is the name of the drug and what does it do? Voranigo (vo-rah-NEE-goh), generic name vorasidenib approved on August 6 2024, is a medicine used to treat certain types of brain tumors called Grade 2 astrocytoma and oligodendroglioma. These tumors must have a specific mutation in the IDH1 or IDH2 genes. It is prescribed for people aged 12 and older after surgery,...
What is it prescribed for? LETYBO approved on February 29, 2024, is indicated to treat moderate-to-severe frown lines in adults. What is the name of the drug and what does it do? Letybo (pronounced leh-TEE-boh), (generic name: letibotulinumtoxinA-wlbg), is a medication indicated for the temporary improvement in the appearance of moderate to severe glabellar lines...
What is Truqap prescribed for? Truquap is perscribed in combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN-alterations as detected by an FDA-approved test following...